Chemistry · Source approval
On a me-too application, equivalence is not one requirement among many. It is the application.
What is five batch analysis?
Five batch analysis is the analytical characterisation of five representative production batches of a technical grade active ingredient, establishing the content of the active and the identity and level of each impurity. It is how CIB&RC determines whether your material is equivalent to the already-registered reference source, and it is central to any Section 9(4) application.
Why the impurity profile decides everything
Two technical materials with the same active ingredient at the same assay are not necessarily the same product. Different synthesis routes, catalysts, solvents and purification steps produce different impurities at different levels. Some of those impurities are toxicologically significant.
The toxicology package accepted for the already-registered reference source was generated on material with a particular impurity profile. If yours differs materially, that package no longer covers your product, and the Registration Committee may require additional toxicology specific to your source.
That is the whole logic of equivalence, and it explains why a 9(4) application that looks routine on paper can become an expensive programme. The question is never simply "is the assay right" but "is this the same material, impurity for impurity".
What the analysis must establish
- Five representative batches from routine production, not specially prepared material
- Active ingredient content in each batch
- Identity of each impurity present above the reporting threshold
- Level of each impurity, batch by batch, showing consistency
- Validated analytical methods for the active and for the impurities
- Impurity reference standards where required for chemical verification
- Manufacturing process description sufficient to explain the impurities observed
Batch selection is not a formality. Batches that do not represent routine production give a profile your commercial material will not match, and the mismatch surfaces later at inspection or on a sample drawn from the market.
Screen the supplier before you sign
This is the practical recommendation this page exists to make. Most equivalence problems are discovered after a supply agreement is signed, sometimes after material has been shipped. At that point the options are all expensive: fund source-specific toxicology, find a new supplier and start again, or abandon the project.
Screening costs a fraction of any of those. Before committing:
- Obtain the manufacturer's five-batch data and full specification
- Compare the impurity profile line by line against the reference specification
- Identify any impurity present that is absent from the reference, or present at a materially higher level
- Establish whether the synthesis route differs, and if so how
- Form a view on whether additional toxicology is likely, and price that risk into the commercial decision
A supplier reluctant to share five-batch data before an agreement is itself informative. Confidentiality can be arranged; refusal usually cannot be worked around.
Common findings and what they mean
| Finding | Typical consequence |
|---|---|
| Impurity profile closely matches the reference | Straightforward equivalence case |
| Minor impurity at slightly higher level | Usually manageable with justification |
| Impurity present that is absent from the reference | Requires identification and a toxicological position |
| Different synthesis route | Expect close scrutiny; additional data may be required |
| Batch-to-batch variability | Indicates process control issues that will recur commercially |
| Data from a facility whose output is not accepted | Repeat the analysis |
Laboratory selection
Five-batch analysis has to be performed at a facility whose data CIB&RC will accept, to validated methods, with proper documentation. Analysis performed at a laboratory that does not meet the expected standard is not a saving; it is a repeat cost plus a lost quarter. We place this work with accredited laboratories and review the protocol before the work begins rather than the report after it.
Frequently Asked Questions
Why five batches specifically?
Five batches from routine production give enough data to characterise the impurity profile and demonstrate batch-to-batch consistency, rather than showing a single favourable result. Consistency is as important as the profile itself.
Can I use the manufacturer's existing analysis?
Sometimes, if it was performed at an acceptable facility, to validated methods, on representative batches, with adequate documentation. Review it before relying on it — overseas data prepared for a different regulatory system often falls short on one of those points.
What if my impurity profile differs from the reference source?
It depends on the difference. A minor impurity at a slightly higher level is usually manageable with justification. A new impurity, or a materially different synthesis route, may require source-specific toxicology, which changes the economics of the project substantially.
Do I need impurity reference standards?
For Section 9(3) submissions, samples of standard impurities are also required for chemical verification. Plan for their preparation as part of the chemistry programme rather than treating it as an afterthought.
Can I change technical supplier after registration?
Not automatically. The registration is tied to the approved source, and a new source requires a fresh equivalence assessment and an application. Where supply security matters, it is worth establishing a second approved source proactively.
Reviewed: 22 September 2026 · Reflects the Insecticides Act, 1968 and Insecticides Rules, 1971 as amended, including the Insecticides Third (Amendment) Rules, 2026 (G.S.R. 597(E) dated 8 July 2026). General guidance only — confirm current requirements before acting.
Evaluating a technical supplier?
Send us their five-batch data before you sign. An equivalence screen now costs a fraction of source-specific toxicology later.
Talk to Our Regulatory Team